# NVE Corp: Form 10-Q for the period ended Dec 31, 2022

- Company: [NVE Corp](/companies/nvec.md) (CIK 724910)
- Form: 10-Q
- Filed: 2023-01-25
- Accepted by EDGAR: Jan 25, 2023, 16:14 ET
- Period: 2022-12-31
- Accession: 0001376474-23-000057
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/724910/000137647423000057/nvec-20221231.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/724910/000137647423000057/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2022-10-01 to 2022-12-31 | $7.4m | us-gaap:Revenues |
| Revenue | 9 months, 2022-04-01 to 2022-12-31 | $25.5m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2022-10-01 to 2022-12-31 | $1.5m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2022-04-01 to 2022-12-31 | $5.5m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2022-10-01 to 2022-12-31 | $5.9m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2022-04-01 to 2022-12-31 | $19.9m | us-gaap:GrossProfit |
| Research and development | 3 months, 2022-10-01 to 2022-12-31 | $700.6k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2022-04-01 to 2022-12-31 | $2.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2022-10-01 to 2022-12-31 | $4.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2022-04-01 to 2022-12-31 | $16.7m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2022-10-01 to 2022-12-31 | $994.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2022-04-01 to 2022-12-31 | $3.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2022-10-01 to 2022-12-31 | $4.2m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2022-04-01 to 2022-12-31 | $14.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2022-10-01 to 2022-12-31 | $0.88 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2022-04-01 to 2022-12-31 | $2.99 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2022-10-01 to 2022-12-31 | $0.88 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2022-04-01 to 2022-12-31 | $2.99 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2022-10-01 to 2022-12-31 | 4,832,368 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2022-04-01 to 2022-12-31 | 4,831,168 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2022-04-01 to 2022-12-31 | $14.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2022-04-01 to 2022-12-31 | $907.6k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2022-04-01 to 2022-12-31 | $14.5m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | at 2022-12-31 | $2.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2022-12-31 | $21.8m | us-gaap:AssetsCurrent |
| Total assets | at 2022-12-31 | $65.7m | us-gaap:Assets |
| Current liabilities | at 2022-12-31 | $1.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2022-12-31 | $2.3m | us-gaap:Liabilities |
| Shareholders' equity | at 2022-12-31 | $63.5m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 11,124 characters.

### Forward-looking statements

Some of the statements made in this Report or in the documents incorporated by reference in this Report and in other materials filed or to be filed by us with the Securities and Exchange Commission (“SEC”) as well as information included in verbal or written statements made by us constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to the safe harbor provisions of the reform act. Forward-looking statements may be identified by the use of the terminology such as may, will, expect, anticipate, intend, believe, estimate, should, or continue, or the negatives of these terms or other variations on these words or comparable terminology. To the extent that this Report contains forward-looking statements regarding the financial condition, operating results, business prospects or any other aspect of NVE, you should be aware that our actual financial condition, operating results and business performance may differ materially from that projected or estimated by us in the forward-looking statements. We have attempted to identify, in context, some of the factors that we currently believe may cause actual future experience and results to differ from their current expectations. These differences may be caused by a variety of factors, including but not limited to risks related to our reliance on several large customers for a significant percentage of revenue, our dependence on critical suppliers and packaging vendors, uncertainties related to the economic environments in the industries we serve, uncertainties related to future sales and revenues, risks and uncertainties related to future stock repurchases and dividend payments, and other specific risks that may be alluded to in this Report or in the documents incorporated by reference in this Report.

Further information regarding our risks and uncertainties are contained in Part I, Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended March 31, 2022 as updated in Item 1A of this report.

### General

NVE Corporation, referred to as NVE, we, us, or our, develops and sells devices that use spintronics, a nanotechnology that relies on electron spin rather than electron charge to acquire, store and transmit information. We manufacture high-performance spintronic products including sensors and couplers that are used to acquire and transmit data.

### Critical accounting policies

A description of our critical accounting policies is provided in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended March 31, 2022. As of December 31, 2022 our critical accounting policies and estimates continued to include investment valuation, inventory valuation, and deferred tax assets estimation.

### Quarter ended December 31, 2022 compared to quarter ended December 31, 2021

The table shown below summarizes the percentage of revenue and quarter-to-quarter changes for various items:

| Revenue | Percentage of Revenue Quarter Ended December 31, 2022 | 2021 | Quarter- to-Quarter Change |
| --- | ---: | ---: | ---: |
| Product sales | 97.3% | 94.1% | 21.7% |
| Contract research and development | 2.7% | 5.9% | (46.2)% |
| Total revenue | 100.0% | 100.0% | 17.7% |
| Cost of sales | 20.0% | 22.0% | 6.7% |
| Gross profit | 80.0% | 78.0% | 20.7% |
| Expenses |  |  |  |
| Research and development | 9.5% | 9.5% | 17.5% |
| Selling, general, and administrative | 5.4% | 4.3% | 48.2% |
| Total expenses | 14.9% | 13.8% | 27.1% |
| Income from operations | 65.1% | 64.2% | 19.4% |
| Interest income | 5.5% | 4.5% | 43.0% |
| Income before taxes | 70.6% | 68.7% | 20.9% |
| Provision for income taxes | 13.4% | 13.6% | 16.2% |
| Net income | 57.2% | 55.1% | 22.1% |

Total revenue for the quarter ended December 31, 2022 (the third quarter of fiscal 2023) increased 18% compared to the quarter ended December 31, 2021 (the third quarter of fiscal 2022). The increase was due to a 22% increase in product sales, partially offset by a 46% decrease in contract research and development revenue. The increase in product sales was primarily due to increased purchases by existing customers and new customers. Sales increased in most of our markets and product lines. The decrease in contract research and development revenue was due to the completion of certain contracts.

Gross profit as a percentage of revenue increased to 80% for the third quarter of fiscal 2023 from 78% for the third quarter of fiscal 2022. The increase was primarily due to increased prices and economies of scale due to increased revenue, partially offset by increased costs.

Total expenses increased 27% for the third quarter of fiscal 2023 compared to the third quarter of fiscal 2022 due to an 18% increase in research and development expense and a 48% increase in selling, general, and administrative expense. The increases in expenses were primarily due to increased employee compensation expenses and increased staffing.

Interest income for the third quarter of fiscal 2023 increased 43% due to an increase in our available-for-sale securities and an increase in their average interest rate.

The 22% increase in net income in the third quarter of fiscal 2023 compared to the prior-year quarter was primarily due to increased revenue and increased interest income, partially offset by increased expenses.

### Nine months ended December 31, 2022 compared to nine months ended December 31, 2021

The table shown below summarizes the percentage of revenue and period-to-period changes for various items:

| Revenue | Percentage of Revenue Nine Months Ended December 31 2022 | , 2021 | Period- to-Period Change |
| --- | ---: | ---: | ---: |
| Product sales | 97.4% | 96.2% | 27.1% |
| Contract research and development | 2.6% | 3.8% | (12.9)% |
| Total revenue | 100.0% | 100.0% | 25.6% |
| Cost of sales | 21.7% | 23.2% | 17.8% |
| Gross profit | 78.3% | 76.8% | 28.0% |
| Expenses |  |  |  |
| Research and development | 7.7% | 10.4% | (6.6)% |
| Selling, general, and administrative | 4.8% | 6.0% | (0.9)% |
| Total expenses | 12.5% | 16.4% | (4.5)% |
| Income from operations | 65.8% | 60.4% | 36.8% |
| Interest income | 4.1% | 4.2% | 19.8% |
| Income before taxes | 69.9% | 64.6% | 35.7% |
| Provision for income taxes | 13.1% | 11.8% | 37.6% |
| Net income | 56.8% | 52.8% | 35.3% |

Total revenue for the nine months ended December 31, 2022 (the first nine months of fiscal 2023) increased 26% compared to the nine months ended December 31, 2021 (the first nine months of fiscal 2022). The increase was due to a 27% increase in product sales, partially offset by a 13% decrease in contract research and development revenue. The increase in product sales was primarily due to increased purchases by existing customers and new customers. Sales increased in most of our markets and product lines. The decrease in contract research and development revenue was due to the completion of certain contracts.

Gross profit as a percentage of revenue increased to 78% for the first nine months of fiscal 2023 from 77% for the first nine months of fiscal 2022. The increase was primarily due to increased prices and economies of scale due to increased revenue, partially offset by increased costs.

Total expenses decreased 5% for the first nine months of fiscal 2023 compared to the first nine months of fiscal 2022 due to an 7% decrease in research and development expense and a 1% decrease in selling, general, and administrative expense. The decrease in research and development expense was primarily due to the reallocation of resources to revenue-generating activities.

Interest income for the first nine months of fiscal 2023 increased 20% due to an increase in our available-for-sale securities and an increase in their average interest rate.

The 35% increase in net income in the first nine months of fiscal 2023 compared to the prior-year period was primarily due to increased revenue and increased interest income.

### Supply Chain Disruptions

Supply chain disruptions may have favorably affected product sales in the quarter and nine months ended December 31, 2022 since we believe the disruptions may have been less severe for us than for our competitors. We may be less susceptible to supply chain disruptions because we have our own wafer fabrication and product test operations. We believe supply chain disruptions had an unfavorable impact on our costs of sales.

### Liquidity and Capital Resources

### Overview

Cash and cash equivalents were $2,029,714 as of December 31, 2022 compared to $10,449,510 as of March 31, 2022. The $8,419,796 decrease in cash and cash equivalents during the first nine months of fiscal 2023 was due to $14,492,478 of cash used in financing activities for dividend payments and $8,676,229 of cash used by investing activities, partially offset by $14,748,911 in net cash provided by operating activities.

### Operating Activities

Net cash provided by operating activities related to product sales and research and development contract revenue as our primary source of working capital for the current and prior-year quarters. Net cash provided by operating activities was $14,748,911 for the first nine months of fiscal 2023 compared to $9,098,330 for the first nine months of fiscal 2022.

Accounts receivable decreased $2,607,555 during the first nine months of fiscal 2023 primarily due to the timing of customer payments.

Inventories increased $1,370,592 due primarily to our decision to increase inventories to support increased product sales and to mitigate longer supplier lead-times and supply-chain risks.

### Investing Activities

Cash used by investing activities during the nine months ended December 31, 2022 consisted of $26,618,617 of marketable securities purchases and $907,612 of fixed asset purchases, partially offset by $18,750,000 in proceeds from maturities of marketable securities and the receipt of a $100,000 tenant improvement allowance. Purchases of fixed assets were primarily capital expenditures for additional production equipment to increase our manufacturing capacity.

### Financing Activities

Cash used in financing activities during the nine months ended December 31, 2022 consisted of $14,492,478 of cash dividends paid to shareholders.

In addition to cash dividends to shareholders paid in third quarter of fiscal 2023, on January 25, 2023 we announced that our Board of Directors had declared a cash dividend of $1.00 per share of Common Stock, or $4,830,826 based on shares outstanding as of January 20, 2023, to be paid February 28, 2023.

We plan to fund dividends through cash provided by operating activities and proceeds from maturities of marketable securities. All future dividends will be subject to Board approval and subject to the company’s results of operations, cash and marketable security balances, estimates of future cash requirements, and other factors the Board may deem relevant. Furthermore, dividends may be modified or discontinued at any time without notice.

## Controls and procedures

As filed, 1,375 characters.

### Disclosure Controls and Procedures

Management, with the participation of the Chief Executive Officer and Chief Financial Officer, has performed an evaluation of our disclosure controls and procedures that are defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (the “Exchange Act”) as of the end of the period covered by this Report. This evaluation included consideration of the controls, processes, and procedures that are designed to ensure that information required to be disclosed by us in the reports we file under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Principal Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Although there have been changes in personnel involved in our controls, processes, and procedures, our management concluded that, as of December 31, 2022, our disclosure controls and procedures were effective.

### Changes in Internal Controls

During the quarter ended December 31, 2022, there was no change in our internal control over financial reporting that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 892 characters.

There have been no material changes from the risk factors disclosed in our Annual Report on Form 10-K for the fiscal year ended March 31, 2022, except the following risk factor is replaced in its entirety by the following to reflect an amendment to an agreement with Abbott Laboratories, which extends the Agreement term through December 31, 2023:

### We may lose revenue if we are unable to renew customer agreements.

We have agreements with certain customers, including a Supplier Partnering Agreement, as amended, with Abbott Laboratories, which expires December 31, 2023. We cannot predict if these agreements will be renewed, or if renewed, under what terms. Although it is possible we could continue to sell products to these customers without formal agreements, an inability to agree on mutually acceptable terms could have a significant adverse impact on our revenue or profitability.

Filed Jan 25, 2023.
Source: SEC EDGAR, the filing index for accession 0001376474-23-000057. Last ingested by Listed: Nov 5, 2026, 19:10 ET. No prices; not investment advice.
